+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa



In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa



Journal of ChemoTherapy 8(5): 358-364



The in-vitro susceptibilities of a total of 174 ciprofloxacin-resistant Enterobacteriaceae and Pseudomonas aeruginosa were determined. According to the BSAC and NCCLS breakpoints, meropenem, aztreonam, ceftibuten, ceftazidime, imipenem and cefotaxime were the most active (> 90%) antimicrobial agents tested against Enterobacteriaceae. Susceptibility of these strains to piperacillin/tazobactam, cefpodoxime and cefixime (84.96%) was higher than that to tobramycin, gentamicin and fosfomycin (50-75%). More than 90% of P. aeruginosa were susceptible to meropenem when both interpretative susceptibility breakpoint criteria were used. Piperacillin, piperacillin/tazobactam and ceftazidime were active against 50-75% of the same strains. Meropenem was the most active antimicrobial tested against all ciprofloxacin-resistant clinical isolates assayed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008835265

Download citation: RISBibTeXText

PMID: 8957715

DOI: 10.1179/joc.1996.8.5.358


Related references

Comparison of the in vitro activity of meropenem and doripenem against Pseudomonas aeruginosa and multidrug-resistant Enterobacteriaceae. Acta Clinica Belgica 65(6): 451, 2011

In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. ChemoTherapy 49(6): 294-297, 2003

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant Pseudomonas aeruginosa Strains. Chemotherapy 49(6): 294-297, 2003

The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. International Journal of Antimicrobial Agents 20(5): 384-386, 2002

In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 25(2): 181-182, 2005

Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae. Infection 11(6): 326-328, 1983

In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa. ChemoTherapy 32(5): 425-430, 1986

Comparative in vitro activity of meropenem against pseudomonas aeruginosa and pseudomonas maltophilia isolated from cystic fibrosis patients including imipenem resistant strains. Abstracts of the General Meeting of the American Society for Microbiology 91: 3, 1991

Comparative in vitro activity of aztreonam the aminoglycosides ciprofloxacin and three beta lactam antibiotics to pseudomonas aeruginosa and the enterobacteriaceae. Abstracts of the Annual Meeting of the American Society for Microbiology 90: 383, 1990

In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. Journal of ChemoTherapy 3(3): 143-146, 1991

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates. Antimicrobial Agents and ChemoTherapy 60(5): 3227-3231, 2016

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrobial Agents and ChemoTherapy 52(1): 333-336, 2008

Ciprofloxacin in vitro activity against community hospital isolates of resistant pseudomonas aeruginosa. Clinical Research 34(4): 923A, 1986

In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Bmc Infectious Diseases 16(1): 444, 2016

In vitro activity of ciprofloxacin against 224 clinical isolates including resistant pseudomonas aeruginosa and staphylococcus epidermidis. Abstracts of the Annual Meeting of the American Society for Microbiology 86: 5, 1986